Top 5 1st Quarter Trades of RP Management, LLC

Author's Avatar
insider
May 12, 2022
Article's Main Image

RP Management, LLC recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

110 EAST 59TH STREET NEW YORK, NY 10022

As of the latest 13F report, the guru’s equity portfolio contained 5 stocks valued at a total of $246,000,000. The top holdings were BHVN(53.58%), BCRX(25.44%), and EPZM(19.42%).

According to GuruFocus data, these were RP Management, LLC’s top five trades of the quarter.

Epizyme Inc


During the quarter, RP Management, LLC bought 22,666,667 shares of NAS:EPZM for a total holding of 31,833,334. The trade had a 13.83% impact on the equity portfolio. During the quarter, the stock traded for an average price of $1.64.

On 05/12/2022, Epizyme Inc traded for a price of $0.4677 per share and a market cap of $73,486,000. The stock has returned -92.77% over the past year.

GuruFocus gives the company a financial strength rating of 2 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, Epizyme Inc has a EV-to-Ebitda ratio of -0.83 and a price-sales ratio of 1.38.

The price-to-GF Value ratio is 0.02, earning the stock a GF Value rank of 2.

BioCryst Pharmaceuticals Inc


The guru established a new position worth 3,846,154 shares in NAS:BCRX, giving the stock a 18% weight in the equity portfolio. Shares traded for an average price of $13.23 during the quarter.

On 05/12/2022, BioCryst Pharmaceuticals Inc traded for a price of $7.94 per share and a market cap of $1,447,836,000. The stock has returned -27.91% over the past year.

GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, BioCryst Pharmaceuticals Inc has a EV-to-Ebitda ratio of -12.75 and a price-sales ratio of 7.52.

The price-to-GF Value ratio is 0.30, earning the stock a GF Value rank of 2.

Biohaven Pharmaceutical Holding Co Ltd


RP Management, LLC reduced their investment in NYSE:BHVN by 1,000,000 shares. The trade had a 27.95% impact on the equity portfolio. During the quarter, the stock traded for an average price of $80.86.

On 05/12/2022, Biohaven Pharmaceutical Holding Co Ltd traded for a price of $140.78 per share and a market cap of $10,056,782,000. The stock has returned 101.90% over the past year.

GuruFocus gives the company a financial strength rating of 2 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Biohaven Pharmaceutical Holding Co Ltd has a EV-to-Ebitda ratio of -14.93 and a price-sales ratio of 19.77.

Cytokinetics Inc


The guru sold out of their 875,656-share investment in NAS:CYTK. Previously, the stock had a 8.33% weight in the equity portfolio. Shares traded for an average price of $23.47 during the quarter.

On 05/12/2022, Cytokinetics Inc traded for a price of $36.9 per share and a market cap of $3,193,930,000. The stock has returned 62.06% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 2 out of 10.

In terms of valuation, Cytokinetics Inc has a price-book ratio of 27.43, a EV-to-Ebitda ratio of -13.05 and a price-sales ratio of 47.61.

The price-to-GF Value ratio is 1.70, earning the stock a GF Value rank of 1.

Viracta Therapeutics Inc


The guru established a new position worth 3,700 shares in NAS:VIRX, giving the stock a 0.02% weight in the equity portfolio. Shares traded for an average price of $10.02 during the quarter.

On 05/12/2022, Viracta Therapeutics Inc traded for a price of $2.04 per share and a market cap of $71,842,000. The stock has returned -78.13% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 2 out of 10.

In terms of valuation, Viracta Therapeutics Inc has a price-book ratio of 0.94 and a EV-to-Ebitda ratio of 0.08.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles